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Introduction
Small non-coding RNAs are known as a clinically relevant category of non-coding RNAs (ncRNAs)
that have gained growing attention for their therapeutic values. miRNA and siRNA are of the
most important and well-documented types of small ncRNAs. These regulatory RNA molecules
are short–approximately 22 nucleotides long–with a similar mechanism of generation in which
they are excised from longer double-stranded RNA precursor molecules. Both miRNA and siRNA
target protein-coding genes via an antisense-based strategy and follow the same processing manner
to reach gene-silencing effect (Chen et al., 2015). Functionally, small ncRNAs play a determining
part in the modulation of cellular gene expression. The impressive role of these molecules as the
controlling machinery of cells has proposed promising capacities for their potential translation
into the clinic. In this context, tuning the regulatory components (such as ncRNAs) rather than the
regulated components (protein-coding gens) has been suggested to be a more convenient andmore
effective approach to correct many cellular dysfunctions (Taft et al., 2010). This emerging concept
symbolizes the dramatic potential of small ncRNAs, as a significant part of the regulatory apparatus
of cells, to treat human diseases.
Small ncRNA Delivery: Active Targeting and the Dream of Magic
Bullet
Within the recent years, nanotechnology-based approaches have emerged as potentially powerful
and efficient systems for cellular delivery of ncRNAs. The exploitation of nanocarriers shows
promise to bypass a variety of biological barriers for systematically administered RNA therapeutics
(Miele et al., 2012; Segovia et al., 2015). Nanoparticles provide protection from serum nucleases
for RNA-based therapeutic molecules, decrease their sequestration by phagocytes of the reticulo-
endothelial system (RES) and are able to carry both hydrophilic and hydrophobic substances
(Aagaard and Rossi, 2007; Peer et al., 2007). The excellent characteristics of nanocarrier platforms
aid in enhancing overall bioavailability, extending in vivo stability, and improving the cellular
delivery of RNA therapeutics such as small ncRNAs.
For the successful delivery of small ncRNA, one of the most important problems that needs to be
solved is targeting of these drugs into the desired sites. The delivery of small ncRNAs to the diseased
cells, tissues or organs not only raises their silencing potency, but also leads to a considerable
reduction of side effects by avoiding normal cells (Daka and Peer, 2012). Active targeting plays
a highly critical part in achieving efficient in vivo biodistribution and optimized systemic delivery
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of ncRNA-based therapeutics. Active targeting becomes possible
when the surface of nanocarriers that are embedded with small
ncRNAs is modified through the covalent attachment of a
cell/tissue-specific ligand. These surface-conjugated ligands will
specifically interact with receptors that are expressed on the
surface of target cells (Bertrand et al., 2014). In this manner,
the delivery of therapeutic small ncRNA molecules will be
poised to materialize the dream of constructing magic bullet;
the concept that was theoretically fathered by Paul Ehrlich to
describe targeted transportation of therapeutic agents to the
desired sites of the body. Peptides are known as one of the
most interesting categories of targeting ligands that have recently
received huge attention. Due to some unique properties, peptides
have become favorable targeting ligands for formulating powerful
and sophisticated drug delivery platforms.
Phage Display Libraries: A Treasure of
Cell-targeting Peptides
Phage display that is defined as the ability to genetically modify
bacteriophages for introducing specific amino acids onto their
surface is a worthwhile tool in biomedicine. The birth of
phage display, as a kind of virus-based molecular chimera,
goes back to three decades ago when Smith for the first
time reported the expression of a foreign polypeptide on the
surface of phage particles (Smith, 1985). The power of phage
display for gaining momentum as a revolutionary strategy for
gene/drug delivery studies comes from two distinctive features:
(i) establishing a physical connection between the phenotype
(the displayed ligand) and the genotype (the DNA sequence
encoding the displayed ligand) within the same viral particle
and (ii) producing very large libraries of ligands displayed
on the surface of the phage particles. The most widely-used
phage display libraries are random peptide libraries (RPL).
In simple terms, a random peptide library is a collection of
phages carrying on their surface extremely diverse types of
peptides.
Due to the phenotype-genotype link, phage peptide libraries
can be screened against any target of interest for selecting target-
specific binders. This screening strategy displays similarity to the
approach of natural selection but with distinctive difference of
being performed in the test tube instead of nature (Bakhshinejad
and Sadeghizadeh, 2014). Affinity selection is a hallmark of
phage display screening through which binding peptides specific
to any target including organic and inorganic structures can
be obtained. The procedure of affinity-based library screening
is called “panning.” Whole cells in the culture are one of the
most important targets used in panning studies. Cell panning
involves incubating the phage library with target cells. Some
phages interact with and bind to the target with higher affinity.
The unbound or weakly-bound phages are then washed away
and the bound phages are recovered. Subsequently, the recovered
phages are amplified through infecting host bacterial cells. This
process is repeated for several rounds to ultimately isolate the
most strongly binding phages whose surface displayed peptides
are identified by DNA sequencing (Bakhshinejad et al., 2014).
Phage Library Selected Peptides and
Targeted Delivery of miRNA/siRNA-based
Nanocarriers
Currently, RPLs are known to be one of the major sources
of clinically relevant peptides. The marriage of combinatorial
peptide chemistry and phage display has turned phage peptide
libraries to a treasure for the discovery of useful targeting
peptides. As we are beginning to more deeply understand the
biological functions of ncRNAs in cellular processes and thereby
their vital roles in the pathogenesis of numerous disorders,
phage peptide libraries are attracting increasing attention for
the delivery of small ncRNAs. Cell-specific peptides derived
from phage libraries have been demonstrated to be capable of
acting as important targeting components in nanocarriers and
delivering both miRNA and siRNA into target cells. A variety of
nanocarriers have been used for the delivery of small ncRNAs
(Conde et al., 2015). Liposomes, polymers, micelles, protamine,
and virus-like particles (VLPs) are delivery platforms that in
different studies have represented potential to achieve delivery
of miRNA and siRNA to target cells/tissues. Table 1 indicates
a list of studies in which peptides selected by phage display
screening have been used for targeted delivery of miRNA/siRNA-
containing nanocarriers to desired cells.
Cancer is a disease that has been the focus of much
investigation for the delivery of small ncRNA-based therapeutics.
Peptides obtained from screening of phage libraries against
various tumor cells have served to target nanocarriers with
encapsulated ncRNAs to the cells of interest. In line with
this, several attempts have been made to identify phage-borne
peptides specific to different tumors. A number of these peptides
have indicated favorable outcomes for the delivery of peptide-
targeted miRNA/siRNA-containing nanocarriers to malignant
cells. DS 4-3, breast cancer-specific peptides, conjugated to
branched polyethylenimine (bPEI) have been indicated to deliver
the tumor suppressor miR-145 to metastatic breast cancer
cells, thereby inhibiting tumor cell growth and suppressing cell
invasion (Lee et al., 2013). In a novel strategy for intracellular
delivery of siRNA into cancer cells, a research group led by
Petrenko targeted liposomes by using preselected intact phage
proteins (Bedi et al., 2011). In this work, not only cancer-
avid peptide but the whole fusion phage coat protein in
combination with its displayed peptide was used as a targeting
ligand. This tumor-specific complex (phage fusion protein
and peptide) was isolated from affinity screening of a phage
library against MCF-7 breast cancer cells followed by being
inserted into the lipid bilayer of liposome. The result was
construction of a siRNA-encapsulated phage protein-targeted
liposome that specifically down-regulated the expression of
PRDM14 gene–a gene with important roles in the carcinogenesis
of breast cancer–and inhibited the synthesis of its protein.
This strategy remarkably overcomes the problem of purification
of targeting peptides and their subsequent conjugation to
nanocarriers.
Phage display selected peptides have also been exploited
for targeted delivery of small ncRNAs involved in disorders
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TABLE 1 | Studies in which peptides obtained through screening of phage display libraries have been used to functionalize the surface of nanocarriers
for targeted delivery of miRNA and siRNA.
Non-coding RNA Nanocarrier Targeting peptide sequence Target Reference
miR-145 Branched polyethylenimine
(bPEI) polymer
CRIMRILRILKLAR
RIMRILRILKLARC
Breast cancer Lee et al., 2013
PRDM14 siRNA Liposome DMPGTVLP (attached to M13
phage fusion protein pVIII)
Breast cancer Bedi et al., 2011
siRNA cocktail against
cyclin family members
VLPs of MS2
bacteriophage
SFSIIHTPILPL Hepatocellular carcinoma Ashley et al., 2011
GAPDH siRNA Phage-like
nanoparticles/Nanophage
VEEGGYIAA
DWRGDSMDS
Breast cancer Bedi et al., 2013
fluorescein-labeled siRNA Protamine KYLAYPDSVHIW LNCaP – prostate cancer Qin et al., 2011
Fas siRNA Poly (cystamine
bisacrylamide-
diaminohexane, CBA-DAH)
polymer
WLSEAGPVVTVRALRGTGSW Primary cardiomyocyte Nam et al., 2010
VEGF siRNA Poly (cystamine
bisacrylamide-
diaminohexane, CBA-DAH)
polymer
WLSEAGPVVTVRALRGTGSW Cardiomyocyte Nam et al., 2012
SHP1 and Fas siRNA Poly (cystamine
bisacrylamide-
diaminohexane, CBA-DAH)
polymer
WLSEAGPVVTVRALRGTGSW Cardiomyocyte Nam et al., 2011
miR-92a Polyelectrolyte complex
micelles
VHPKQHR Endothelial cells Kuo et al., 2014
other than cancer. Cardiovascular diseases, as one of the
leading causes of death worldwide, have attracted attention to
obtain benefits from achievements of phage display technology
in the development of targeted therapy approaches. Since
cardiomyocyte apoptosis is an important player in several
heart diseases, the inhibition of this type of cell death has
been viewed as a useful strategy for potential treatment of
pathological conditions linked to cardiovascular system. This can
be achieved through abolishing the activity of those factors whose
function stimulates apoptosis. The conjugation of a primary
cardiomyocyte (PCM) specific peptide selected by phage display
to a polymer-based nanocarrier was used for the delivery of
siRNA specific to Fas (an apoptosis inducer) to cardiomyocytes
under hypoxic conditions (Nam et al., 2010). This PCM-targeted
siRNA delivery system led to the prevention of apoptosis through
down-regulating the Fas gene. Sometimes the inhibitors of
ncRNAs, not ncRNAs themselves, have to be delivered to target
cells. The exploitation of miRNA inhibitors is a prime example
of miRNA-based scenarios that can be used for therapeutic
purposes. As dysregulated miRNAs are associated with some
disorders, the ability to inhibit the cellular activity of these
miRNAs can provide new opportunities to treat human diseases.
In this context, a micelle-based nanocarrier targeted with a phage
display selected peptide specific to vascular endothelial cells was
shown to successfully deliver miR-92a inhibitor to endothelial
cells; a strategy that is helpful for cell-specific delivery and
targeted inhibition of miRNAs that contribute to the pathology
of atherosclerosis (Kuo et al., 2014).
Conclusion
The capacity of small ncRNAs in specifically silencing the
expression of disease-associated genes underlines their
importance as novel forms of therapeutic intervention in
numerous human disorders. Nanocarriers, due to some
tunable features, represent huge potential to overcome delivery
issues concerned with miRNA/siRNA-based pharmaceutical
platforms. Recent findings highlight the significance of phage
display methodology in providing a wide variety of peptides
to be used for targeting of nanocarriers to desired cells.
Although still in its infancy, phage peptide libraries are
receiving growing attention for targeted cellular delivery
of miRNA/siRNA therapeutic cargoes. Active targeting
of nanocarriers through surface modification with phage
selected peptides will provide new opportunities for taking
advantage of the tremendous potential of small ncRNAs in
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the clinical setting. The quickly advancing role played by
phage peptide libraries in the territory of targeted delivery
of RNA therapeutics has roots in the surprising diversity of
these libraries and the convenience of their screening over a
wide variety of cellular targets that cover numerous human
diseases. Cell-targeting peptides derived from phage display
libraries have raised hopes for researchers to take great strides
toward the cherished goal of targeted delivery of miRNAs and
siRNAs into the same cells that should take these therapeutic
agents.
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